IRLAB to present at ABGSC Investor Day in Stockholm on March 8, 2023
Kurs
+1,00%
Likviditet
0,62 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-11 | 07:00 | Bokslutskommuniké 2025 |
| 2025-10-29 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-09 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-22 | N/A | X-dag ordinarie utdelning IRLAB A 0.00 SEK |
| 2025-05-21 | N/A | Årsstämma |
| 2025-05-07 | 07:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-12 | - | Bokslutskommuniké 2024 |
| 2024-10-30 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-10 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-23 | - | X-dag ordinarie utdelning IRLAB A 0.00 SEK |
| 2024-05-22 | - | Årsstämma |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-07 | - | Bokslutskommuniké 2023 |
| 2023-10-25 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-30 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-21 | - | X-dag ordinarie utdelning IRLAB A 0.00 SEK |
| 2023-06-20 | - | Årsstämma |
| 2023-05-10 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-11-09 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | X-dag ordinarie utdelning IRLAB A 0.00 SEK |
| 2022-05-11 | - | Årsstämma |
| 2022-05-11 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-23 | - | Bokslutskommuniké 2021 |
| 2021-11-10 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-07 | - | X-dag ordinarie utdelning IRLAB A 0.00 SEK |
| 2021-05-06 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-24 | - | Bokslutskommuniké 2020 |
| 2020-11-11 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-26 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-08 | - | X-dag ordinarie utdelning IRLAB A 0.00 SEK |
| 2020-05-07 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-06 | - | Bokslutskommuniké 2019 |
| 2019-11-07 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-28 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-28 | - | Split IRLAB A 1:5 |
| 2019-04-26 | - | X-dag ordinarie utdelning IRLAB A 0.00 SEK |
| 2019-04-25 | - | Årsstämma |
| 2019-04-25 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-14 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-29 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | X-dag ordinarie utdelning IRLAB A 0.00 SEK |
| 2018-05-16 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-11-15 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-29 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-16 | - | Årsstämma |
| 2017-05-16 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-27 | - | Bokslutskommuniké 2016 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Gothenburg, Sweden, March 6, 2023 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will present at the ABGSC Investor Day on Wednesday, March 8, 2023, in Stockholm, Sweden.
Nicholas Waters, EVP and Head of R&D, and Viktor Siewertz, CFO, will participate in the event. The company will be presented at 11:15-11:45 CET on March 8, 2023. This event is held at Haymarket by Scandic, Hötorget 13-15, Stockholm, and is live streamed.
More information can be found on the event webpage at: https://cr.abgsc.com/artiklar/2023/02/abgsc-investor-days-7-8-march/.
For more information
Gunnar Olsson, CEO
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se
Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se
About IRLAB
IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's. In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam.
IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its proprietary systems biology-based Integrative Screening Process (ISP) research platform. In addition to IRLAB’s strong clinical pipeline, the company is also progressing three preclinical programs, IRL942, IRL757, and IRL1117, towards Phase I studies. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.